Digital Health Global

MARCH 2, 2023

Koneksa’s digital biomarker solutions include an industry-leading platform that gives research sponsors and clinical sites the ability to seamlessly aggregate data in real-time from devices, ePROs, patient diaries, and clinical assessments to provide the full picture of an individual’s health.

Life Science 88

Life Science Drug Development BioTech Leadership 88

Healthcare IT Today

NOVEMBER 14, 2022

Brad Whitmore is a successful investor who has targeted a broad range of investments across various industries with an emphasis on businesses with long-term, sustainable competitive advantages and unique offerings relative to competitors. Within Life Sciences, the firm focuses on MedTech, Diagnostics, and Opportunistic Drug Development.

Life Science 96

Life Science HIPAA Drug Development healthcare technology 96

Digital Health Global

JUNE 20, 2023

These individuals have personally built leading technology platforms supercharging drug development globally. Their buy-in shows that our platform is differentiated and poised to unlock truly novel therapies for currently underserved patient populations through efficient, simulation-guided development. Jane Rhodes, Ph.D.,

BioTech 88

BioTech Life Science Leadership Drug Development 88